全文获取类型
收费全文 | 136484篇 |
免费 | 10075篇 |
国内免费 | 237篇 |
专业分类
耳鼻咽喉 | 1292篇 |
儿科学 | 3862篇 |
妇产科学 | 2888篇 |
基础医学 | 21315篇 |
口腔科学 | 3755篇 |
临床医学 | 11412篇 |
内科学 | 27471篇 |
皮肤病学 | 2394篇 |
神经病学 | 13491篇 |
特种医学 | 5621篇 |
外国民族医学 | 20篇 |
外科学 | 17482篇 |
综合类 | 588篇 |
现状与发展 | 1篇 |
一般理论 | 122篇 |
预防医学 | 14971篇 |
眼科学 | 2227篇 |
药学 | 8241篇 |
中国医学 | 247篇 |
肿瘤学 | 9396篇 |
出版年
2023年 | 536篇 |
2021年 | 1879篇 |
2020年 | 1519篇 |
2019年 | 2199篇 |
2018年 | 2760篇 |
2017年 | 2340篇 |
2016年 | 2597篇 |
2015年 | 2870篇 |
2014年 | 3926篇 |
2013年 | 5143篇 |
2012年 | 7870篇 |
2011年 | 7962篇 |
2010年 | 4186篇 |
2009年 | 4346篇 |
2008年 | 7109篇 |
2007年 | 7324篇 |
2006年 | 7067篇 |
2005年 | 6692篇 |
2004年 | 5770篇 |
2003年 | 5490篇 |
2002年 | 4936篇 |
2001年 | 4861篇 |
2000年 | 4804篇 |
1999年 | 4293篇 |
1998年 | 1616篇 |
1997年 | 1337篇 |
1996年 | 1399篇 |
1995年 | 1244篇 |
1994年 | 1157篇 |
1993年 | 1073篇 |
1992年 | 2982篇 |
1991年 | 2721篇 |
1990年 | 2607篇 |
1989年 | 2429篇 |
1988年 | 2243篇 |
1987年 | 1961篇 |
1986年 | 1867篇 |
1985年 | 1779篇 |
1984年 | 1254篇 |
1983年 | 1089篇 |
1982年 | 579篇 |
1981年 | 509篇 |
1980年 | 451篇 |
1979年 | 947篇 |
1978年 | 570篇 |
1977年 | 499篇 |
1974年 | 490篇 |
1973年 | 487篇 |
1972年 | 475篇 |
1971年 | 452篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
62.
Mark P. van Opijnen Linda Dirven Ida E.M. Coremans Martin J.B. Taphoorn Ellen H.W. Kapiteijn 《International journal of cancer. Journal international du cancer》2020,146(6):1479-1489
Patients with melanoma brain metastases (MBM) still have a very poor prognosis. Several treatment modalities have been investigated in an attempt to improve the management of MBM. This review aimed to evaluate the impact of current treatments for MBM on patient- and tumor-related outcomes, and to provide treatment recommendations for this patient population. A literature search in the databases PubMed, Embase, Web of Science and Cochrane was conducted up to January 8, 2019. Original articles published since 2010 describing patient- and tumor-related outcomes of adult MBM patients treated with clearly defined systemic therapy were included. Information on basic trial demographics, treatment under investigation and outcomes (overall and progression-free survival, local and distant control and toxicity) were extracted. We identified 96 eligible articles, comprising 95 studies. A large variety of treatment options for MBM were investigated, either used alone or as combined modality therapy. Combined modality therapy was investigated in 71% of the studies and resulted in increased survival and better distant/local control than monotherapy, especially with targeted therapy or immunotherapy. However, neurotoxic side-effects also occurred more frequently. Timing appeared to be an important determinant, with the best results when radiotherapy was given before or during systemic therapy. Improved tumor control and prolonged survival can be achieved by combining radiotherapy with immunotherapy or targeted therapy. However, more randomized controlled trials or prospective studies are warranted to generate proper evidence that can be used to change the standard of care for patients with MBM. 相似文献
63.
64.
Henrieke W. Schutte MD Guido B. van den Broek MD PhD Stefan C. A. Steens MD PhD Rosella P. M. G. Hermens PhD Jimmie Honings MD PhD Henri A. M. Marres MD PhD Matthias A. W. Merkx MD PhD Willem L. J. Weijs MD Anne I. J. Arens MD Adriana C. H. van Engen–van Grunsven MD PhD Carla M. L. van Herpen MD PhD Johannes H. A. M. Kaanders MD PhD Frank J. A. van den Hoogen MD PhD Robert P. Takes MD PhD 《Cancer》2020,126(17):3982-3990
65.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
66.
Sanne J. H. van Rooij Ryan D. Smith Anaïs F. Stenson Timothy D. Ely Xinyi Yang Nim Tottenham Jennifer S. Stevens Tanja Jovanovic 《Depression and anxiety》2020,37(4):303-312
Most studies investigating the effect of childhood trauma on the brain are retrospective and mainly focus on maltreatment, whereas different types of trauma exposure such as growing up in a violent neighborhood, as well as developmental stage, could have differential effects on brain structure and function. The current magnetic resonance imaging study assessed the effect of trauma exposure broadly and violence exposure more specifically, as well as developmental stage on the fear neurocircuitry in 8‐ to 14‐year‐old children and adolescents (N = 69). We observed reduced hippocampal and increased amygdala volume with increasing levels of trauma exposure. Second, higher levels of violence exposure were associated with increased activation in the amygdala, hippocampus, and ventromedial prefrontal cortex during emotional response inhibition. This association was specifically observed in children younger than 10 years. Finally, increased functional connectivity between the amygdala and brainstem was associated with higher levels of violence exposure. Based on the current findings, it could be hypothesized that trauma exposure during childhood results in structural changes that are associated with later risk for psychiatric disorders. At the same time, it could be postulated that growing up in an unsafe environment leads the brain to functionally adapt to this situation in a way that promotes survival, where the long‐term costs or consequences of these adaptations are largely unknown and an area for future investigations. 相似文献
67.
68.
Glasdam Stinne Ekstrand Frida Rosberg Maria van der Schaaf Ann-Margrethe 《Medicine, health care, and philosophy》2020,23(1):141-152
Medicine, Health Care and Philosophy - Palliative care philosophy is based on a holistic approach to patients, but research shows that possibilities for living up to this philosophy seem limited by... 相似文献
69.
Anna Dietz Nahide Dalda Svenja Zielke Jessica Dittmann Sjoerd J.L. van Wijk Meike Vogler Simone Fulda 《International journal of cancer. Journal international du cancer》2020,147(5):1485-1498
Copy number gains and increased expression levels of cellular Inhibitor of Apoptosis protein (cIAP)1 and cIAP2 have been identified in primary diffuse large B-cell lymphoma (DLBCL) tissues. Second mitochondria-derived activator of caspases (Smac) mimetics were designed to antagonize IAP proteins. However, since their effect as single agents is limited, combination treatment represents a strategy for their clinical development. Therefore, we investigated the Smac mimetic BV6 in combination with proteasome inhibitors and analyzed the molecular mechanisms of action. We discovered that BV6 treatment sensitizes DLBCL cells to proteasome inhibition. We show a synergistic decrease in cell viability and induction of apoptosis by BV6/Carfilzomib (CFZ) treatment, which was confirmed by calculation of combination index (CI) and Bliss score. BV6 and CFZ acted together to trigger activation of BAX and BAK, which facilitated cell death, as knockdown of BAX and BAK significantly reduced BV6/CFZ-mediated cell death. Activation of BAX and BAK was accompanied by loss of mitochondrial membrane potential (MMP) and activation of caspases. Pretreatment with the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) rescued BV6/CFZ-induced cell death, confirming caspase dependency. Treatment with CFZ alone or in combination with BV6 caused accumulation of NOXA, which was required for cell death, as gene silencing by siRNA or Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated NOXA inactivation inhibited BV6/CFZ-induced cell death. Together, these experiments indicate that BV6 and CFZ cooperatively induce apoptotic cell death via the mitochondrial pathway. These findings emphasize the role of Smac mimetics for sensitizing DLBCL cells to proteasome inhibition with important implications for further (pre)clinical studies. 相似文献